Analytical Performance/Clinical Utility Of Laboratory Te
Analytical Performance/Clinical Utility Of Laboratory Te
批准号:
7332041
负责人:
Gyorgy Csako
金额:
$0.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
中文摘要
动脉粥样硬化血栓形成是一种多因素疾病,目前估计有数百种动脉粥样硬化血栓形成的危险因素。除了血清脂类(总胆固醇和甘油三酯)等经典风险因素外,脂蛋白、载脂蛋白和各种炎症分子,如C反应蛋白、血清淀粉样蛋白A和止血因素也被考虑为风险和/或需要处理的因素。为了预防血栓形成,华法林的有效性和安全性需要在治疗范围内保持国际标准化比例。在一项回溯性研究中,我们试图确定来自广泛地理区域的350名门诊护理患者的非治疗性国际标准化比率结果的预测因素。用Logistic回归模型对可能的预测因素(性别、年龄、体重、体重指数、身高、种族、吸烟、饮酒、华法林剂量、治疗适应症、方案强度、国际标准化比率监测频率/类别、相互作用的药物、不良事件)进行评估。亚组分析包括146例同时监测毛细血管全血INR(CoaguChek)的患者。静脉标本检测显示,52%(182/350)的患者有治疗下国际标准化比率结果,13%(44/350)的患者有超治疗国际标准化比率结果,尽管75%的患者经常监测(<lt;或=4wk)。由于样本量小,超治疗国际标准化比率结果无法进一步分析。在测试的19个预测因素中,只有每日华法林剂量(p<;0.02)和方案强度(p<;0.03)是亚治疗结果的显著独立和相加预测因素。接受高强度方案(国际标准化比率2.5-3.5)并接受华法林或=6毫克/天的患者有50%的风险出现亚治疗国际标准化比率结果。亚治疗性CoaguChek结果是亚治疗性静脉穿刺术国际标准化比率结果的独立预测因子(p=0.001)。我们的结论是,在没有易于识别的预测因素的情况下,只有更高的华法林剂量和/或更频繁的监测(可能使用护理点/家庭监测设备)才能最大限度地减少国际正常化比率亚治疗的时间,特别是在接受低剂量和/或高强度抗凝治疗的患者中。
在一项合作研究中,评估了粒细胞集落刺激因子对冠心病患者的潜在益处。提示骨髓祖细胞动员细胞因子可促进心肌血管新生,减轻心肌缺血。应用粒细胞集落刺激因子后,血小板和凝血功能指标无明显变化,但C反应蛋白由治疗前的4.5±1.3 mg/L升至8.6±1.3 mg/L(p=0.017)。此外,粒细胞集落刺激因子从骨髓中动员具有内皮祖细胞潜能的细胞,但没有客观证据表明对心脏有益,在一些患者中具有潜在的不良后果。
在另一项合作研究中,研究了肠外补充L-精氨酸对犬脓毒症模型的影响。感染性休克有两种说法,一种是L精氨酸缺乏状态,另一种是L精氨酸代谢的终产物--一氧化氮过多引起的综合征。在所采用的犬脓毒症模型中,主要测量血流动力学、血浆精氨酸和鸟氨酸、血清硝酸盐/亚硝酸盐、器官损伤的实验室研究和存活。两种不同剂量的L精氨酸均可类似地增加死亡率(p=0.02),并加重休克(平均动脉压降低时p=0.001),提示在感染性休克的危重患者中应避免补充剂量高于标准饮食习惯的L精氨酸。
英文摘要
Atherothrombosis is a multifactorial disease and risk factors for atherothrombosis are now estimated to be in the hundreds. In addition to classical risk factors like serum lipids (total cholesterol and triglycerides), lipoproteins, apolipoproteins, and a variety of inflammatory molecules such as C-reactive protein, serum amyloid A, and hemostatic factors have been also considered for risk and/or require management. For thrombosis prevention, the effectiveness and safety of warfarin require maintaining an international normalized ratio within the therapeutic range. In a retrospective study, we attempted to identify predictors of nontherapeutic international normalized ratio results in 350 ambulatory care patients from a broad geographic region. Possible predictors (gender, age, body weight, body mass index, height, race, tobacco use, alcohol use, warfarin dose, therapeutic indication, regimen intensity, international normalized ratio monitoring frequency/category, interacting medications, adverse events) were assessed with logistic regression models. Subset analysis involved 146 patients concurrently monitored with capillary whole blood INR (CoaguChek). As measured on venous specimens, 52% (182/350) of the patients had subtherapeutic international normalized ratio results and 13% (44/350) had supratherapeutic international normalized ratio results despite frequent (< or =4 wk) monitoring in 75% of the patients. Due to the small sample size, supratherapeutic international normalized ratio results could not be further analyzed. Of 19 predictors tested, only daily warfarin dose (p < 0.02) and regimen intensity (p < 0.03) were significant independent and additive predictors of subtherapeutic results. Patients on the high-intensity regimen (international normalized ratio 2.5-3.5) and receiving warfarin < or =6 mg/day had >50% risk of having subtherapeutic international normalized ratio results. Subtherapeutic CoaguChek results were independent predictors of subtherapeutic venipuncture international normalized ratio results in the subset (p = 0.001). We concluded that, in the absence of readily identifiable predictors, only higher warfarin dosing and/or more frequent monitoring (possibly with point-of-care/home monitoring devices) may minimize the time that international normalized ratio are subtherapeutic, especially in patients receiving low-dose and/or high-intensity anticoagulation therapy.
In a collaborative study, the potential benefit of granulocyte colony-stimulating factor administration to coronary artery disease patients was evaluated. It was suggested that cytokine mobilization of progenitor cells from bone marrow may promote myocardial neovascularization with relief of ischemia. After administration of granulocyte colony-stimulating factor, indices of platelet and coagulation activation were not changed, but C-reactive protein increased from 4.5 +/- 1.3 mg/L to 8.6 +/- 1.3 mg/L (p = 0.017). Further, granulocyte colony-stimulating factor mobilized cells with endothelial progenitor potential from bone marrow, but without objective evidence of cardiac benefit and with the potential for adverse outcomes in some patients.
In another collaborative study, the effect of parenteral L-arginine supplementation was studied in a canine model of sepsis. Septic shock has been alternatively viewed as an L-arginine-deficient state or as a syndrome caused by excess nitric oxide, an end-product of L-arginine metabolism. In the canine sepsis model employed, the main measurements were hemodynamics, plasma arginine and ornithine, serum nitrate/nitrite, laboratory studies for organ injury, and survival. Two different doses of L-arginine both similarly increased mortality (p=0.02), and worsened shock (p=0.001 for reduced mean arterial pressure), suggesting that supplemental parenteral L-arginine, at doses above standard dietary practices, should be avoided in critically ill patients with septic shock.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analytical and Clinical Studies on Factors Involved in Atherosclerosis
-
批准号:6227894
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Analytical Performance and Clinical Utility of Lab Tests for Study of Artherotho
-
批准号:6431869
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Analytical Performance/Clinical Utility Of Lab Tests
-
批准号:7215829
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Laboratory Testing for Endocrine Abnormalities
-
批准号:7593107
-
项目类别:
-
资助金额:$1.4万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Detection and diagnostic utility of paraproteins in body fluids
-
批准号:7593143
-
项目类别:
-
资助金额:$3.9万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Analytical Performance And Clinical Utility Of Thyroid F
-
批准号:6675221
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Development And Clinical Application Of Molecular Diagno
-
批准号:6825480
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Development and Clinical Application of Molecular Diagnostic Tests
-
批准号:6431870
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Analytical Performance/Clinical Utility Of Laboratory Tests For Atherothrombosis
-
批准号:7593108
-
项目类别:
-
资助金额:$2.6万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Detection and diagnostic utility of paraproteins in body fluids
-
批准号:7733671
-
项目类别:
-
资助金额:$4.22万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Analytical Performance and Clinical Utility of Thyroid Function Tests
-
批准号:6431868
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Performance Utility Of Tests For Artherothrombosis
-
批准号:6543089
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Development/ Application Of Molecular Diagnostic Tests
-
批准号:6543091
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Laboratory Testing for Endocrine Abnormalities
-
批准号:7215828
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Development And Clinical Application Of Diagnostic Tests
-
批准号:7215830
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Laboratory Testing for Endocrine Abnormalities
-
批准号:7332038
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Development And Clinical Application Of Molecular Diagno
-
批准号:7332044
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Performance And Utility Of Thyroid Function Tests
-
批准号:6543088
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Analytical Performance/Clinical Utility Of Laboratory Te
-
批准号:7004765
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
Development and Clinical Application of Molecular Diagnostic Tests
-
批准号:6227895
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Gyorgy Csako
-
依托单位:
海外基金